Get insight from foundation experts on research, treatment and prevention, plus the very latest news and events.
Switch on your HIV smarts.
A pair of new drugs—Merck’s doravirine and Gilead Sciences’ bictegravir—showed potent activity against HIV in clinical trials, researchers reported at the Conference on Retroviruses and Opportunistic Infections (CROI) last week … Read More
Twice a month, the San Francisco AIDS Foundation program Positive Force hosts free The Dr. Is In events for our HIV-positive community. Dr. Neal Sheran, the Special Populations Clinical Chief … Read More
Antiretroviral therapy (ART) using just two approved drugs—dolutegravir and rilpivirine —kept HIV suppressed for a year in people with undetectable viral load who switched from a three- or four-drug combo, … Read More
Join us for daily news and commentary on HIV/AIDS treatment, prevention and policy.
The foundation's ongoing forum series bringing research and evidence to bear on timely policy and programmatic issues.